Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

4.570 +0.150 (+3.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
Understanding Compass Pathways's Unusual Options Activity
On Thursday, shares of Compass Pathways (NASDAQ:CMPS) saw unusual options activity. After the option alert, the stock price moved up to $38.2. Sentiment: NEUTRAL Option Type:... 
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
3 Top Psychedelic Stocks to Buy Now
These companies developing hallucinogens have more than meets the eye. 
Via The Motley Fool
Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study
Compass Pathways (NASDAQ:CMPS), a biotech company in the p... 
Via Benzinga
Pandemic Fallout: 6 Mental Health Stocks To Watch
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
Upgrades For Toll Brothers Inc (NYSE: 
Via Benzinga
Atai IPO Day An Underwhelming Event
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End
Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Is ATAI Stock A Buy After The IPO?
ATAI Life Sciences will go public this week. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock. 
Via Talk Markets
Here's How This Psychedelic Drug CEO Sees The Industry Evolving
Competition within legal psychedelic drugs has only barely taken shape. Companies focused on therapy will be the ultimate winners, one CEO said. 
Via Investor's Business Daily
What Do You Really Know About Psychedelics And Psychedelics Stocks?
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That... 
Via Benzinga
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York
Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ... 
Via Benzinga
Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price
Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at... 
Via Talk Markets
Meet PsyBio, A Company Producing Psilocybin From Genetically-Modified Bacteria
As psychedelics draw closer to legalization, companies in the industry have yet to figure out the most efficient and cost-effective way of producin... 
Via Benzinga
Cannabis Countdown: Top 10 Marijuana and Psychedelics Industry News Stories of the Week
Welcome to the Cannabis... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week
Welcome to the Cannabis... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
How Risky Are Psychedelic Stocks?
Public and private companies are studying the use of psilocybin ("magic mushrooms") to treat severe depression, and MDMA (ecstasy) to treat post-traumatic stress disorder. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Is Compass Pathways a Buy?
The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic mushrooms." Will this be a money-maker? 
Via The Motley Fool
Topics Cannabis Law Enforcement
Exposures Cannabis Legal
Can Psychedelics Actually Cure Depression and PTSD?
There is now data suggesting that magic mushrooms and ecstasy -- combined with talk therapy -- may help people with severe depression and post-traumatic stress disorder. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Psychedelic Drug Developer Sets Sights On This Age-Old Hallucinogen
MindMed stock fell after it said a Swiss ethics committee cleared it to begin a study on the effects of the hallucinogen mescaline. 
Via Investor's Business Daily
Compass Pathways Offers Chance on Exploratory Mental Health Treatments
Over the past year, CMPS stock has been going nowhere fast. However, there's been recent progress in advancing psilocybin-assisted therapy. 
Via InvestorPlace
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa... 
Via Benzinga
Exposures Product Safety
Compass Releases Q1 Earnings: Strong Cash Position For Psilocybin R&D Efforts
Compass Pathways (NASDAQ:CMPS), a company researching psyc... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.